Physician profile
Pooja Lothe
NPI 1831485499
$2,118.56
in general payments reported to CMS, 2019-2025
27 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $311 · 2021: $238 · 2022: $194 · 2023: $170 · 2024: $234 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.36 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $306.02 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $302.55 | 2019-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $203.12 | 2019-2025 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $187.72 | 2019-2025 | |
| Janssen Biotech, INC. | $146.31 | 2019 | |
| Seagen INC. | $113.20 | 2019 | |
| Lilly USA, LLC | $100.05 | 2019-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $99.95 | 2025 | |
| Pfizer INC. | $75.87 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $58.91 | 2019-2021 | |
| Genentech USA, INC. | $58.11 | 2019-2022 | |
| Blue Earth Diagnostics | $52.48 | 2021 | |
| Amgen INC. | $48.72 | 2019-2021 | |
| Dova Pharmaceuticals | $42.45 | 2020 | |
| Foundation Medicine, INC. | $41.88 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.05 | 2021-2025 | Enhertu |
| Glaxosmithkline, LLC. | $33.21 | 2020 | |
| Abbvie INC. | $29.76 | 2020 | |
| Sobi, INC | $26.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.76 | 2025 | Ninlaro |
| Astellas Pharma US INC | $23.92 | 2024 | Xtandi |
| Blueprint Medicines Corporation | $22.28 | 2024 | Ayvakit |
| Fortovia Therapeutics, INC. | $18.43 | 2019 | |
| Tempus Ai, INC | $18.05 | 2024 | |
| Amag Pharmaceuticals, INC. | $15.64 | 2020 | |
| Rigel Pharmaceuticals, INC. | $15.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Lothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.